TScan Therapeutics (NASDAQ:TCRX) Earns “Outperform” Rating from Wedbush

Wedbush reissued their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a report issued on Tuesday, RTT News reports. The brokerage currently has a $10.00 price objective on the stock.

Several other research analysts have also issued reports on TCRX. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a report on Monday, August 12th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $12.00.

TScan Therapeutics Price Performance

Shares of NASDAQ:TCRX opened at $5.29 on Tuesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.77 and a quick ratio of 7.77. TScan Therapeutics has a 1-year low of $3.73 and a 1-year high of $9.69. The business has a 50-day moving average price of $5.35 and a two-hundred day moving average price of $6.60.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. TScan Therapeutics had a negative net margin of 855.84% and a negative return on equity of 59.83%. The business had revenue of $0.54 million during the quarter, compared to the consensus estimate of $1.55 million. On average, equities research analysts expect that TScan Therapeutics will post -1.17 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Zoran Zdraveski sold 164,686 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the sale, the insider now owns 4,716 shares of the company’s stock, valued at $27,258.48. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Barbara Klencke purchased 5,000 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were bought at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the acquisition, the director now directly owns 40,000 shares in the company, valued at approximately $221,200. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Zoran Zdraveski sold 164,686 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the transaction, the insider now owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 15,000 shares of company stock worth $82,550. Corporate insiders own 2.76% of the company’s stock.

Institutional Investors Weigh In On TScan Therapeutics

Several institutional investors have recently bought and sold shares of TCRX. Dimensional Fund Advisors LP acquired a new stake in shares of TScan Therapeutics in the second quarter valued at approximately $70,000. SG Americas Securities LLC bought a new position in TScan Therapeutics in the third quarter valued at $78,000. The Manufacturers Life Insurance Company acquired a new stake in TScan Therapeutics in the 2nd quarter valued at $90,000. Cornercap Investment Counsel Inc. bought a new stake in TScan Therapeutics during the 2nd quarter worth about $134,000. Finally, Rhumbline Advisers bought a new position in shares of TScan Therapeutics in the 2nd quarter valued at about $274,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.